Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframeMIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selectionCash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarter of 2027Abs ...